# A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

> **NCT03609294** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 67 (actual)

## Conditions studied

- Hypertension
- Diabetes

## Interventions

- **DRUG:** Treatment A (Fimasartan, Linagliptin)
- **DRUG:** Treatment B (Fimasartan/Linagliptin)

## Key facts

- **NCT ID:** NCT03609294
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2019-03-04
- **Final completion:** 2019-06-30
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609294, "A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03609294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*